Cite
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.
MLA
Orzan, Olguța Anca, et al. “An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.” Pharmaceutics, vol. 15, no. 8, Aug. 2023, p. 2171. EBSCOhost, https://doi.org/10.3390/pharmaceutics15082171.
APA
Orzan, O. A., Țieranu, C. G., Olteanu, A. O., Dorobanțu, A. M., Cojocaru, A., Mihai, M. M., Popa, L. G., Gheorghiu, A. M., Giurcăneanu, C., & Ion, A. (2023). An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics, 15(8), 2171. https://doi.org/10.3390/pharmaceutics15082171
Chicago
Orzan, Olguța Anca, Cristian George Țieranu, Andrei Ovidiu Olteanu, Alexandra Maria Dorobanțu, Anca Cojocaru, Mara Mădălina Mihai, Liliana Gabriela Popa, Ana Maria Gheorghiu, Călin Giurcăneanu, and Ana Ion. 2023. “An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.” Pharmaceutics 15 (8): 2171. doi:10.3390/pharmaceutics15082171.